Alternative Financing Strategies For Medtech Start-Ups
This article was originally published in Start Up
Executive Summary
Pools of venture capital for life science companies are drying up. The good news is that there are alternative sources for young medtech companies. EBI convened a panel of experts at its recent IN3 conference to explain when and where to find them and presents here a Q&A with an angel investor, a representative from a venture debt firm, and an expert in non-dilutive grant funding.
You may also be interested in...
Medtech in Ireland -- Turning Green into Gold
Despite the recent downturn in the national economy, Ireland's medical device community is on the verge of a major growth spurt. A lot of the credit goes to strong government support, particularly in the form of Enterprise Ireland, which serves as a major investor in medtech start-ups. Even with such support, Ireland's medtech start-up community faces many of the challenges that any start-up community faces. But the sector has high hopes and great ambitions. The second of a two-part series.
Ireland's Medtech Explosion
Over the last three decades, Ireland has built a robust medical device community serving large multi-national device companies, built on favorable tax policies and a strong manufacturing and engineering base. But now Ireland is trying to incubate a robust start-up community as well, focused on R&D and innovation, hoping to create the next Medtroniic or Covidien rather than simply serving the current ones.
START-UP's 2011 Life Science Venture Capital Survey: Device Investors Feel The Sting Of FDA, Economy And Reform
START-UP's first life science venture survey asked all VCs how they feel about the state of the industry. Medical device VCs' answers reveal feelings of being beaten down by the FDA and the recession, and general concerns about the sector's ability to generate returns. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."